Transcendence
Bluelighter
- Joined
- Jul 19, 2006
- Messages
- 2,505
The FDA phase 3 s-ketamine trials are a frustrating waste of time. What is the problem with patenting a relatively unknown but easily synthesized analogue as close as a simple halogen substitution. 2-F ketamine has superior and longer lasting remission from depression, less risk of psychosis and would be impossible to abuse in any practical sense if administered in a transdermal patch at sub-recreational doses (say 100mg time-released over 12 or 24 hours) used in the s-ketamine and racemic nasal sprays. I don't understand why low-key and very limited grey market availability precludes established arlhexocyclomines like mxe, mxm, and 2F-ketamine from being considered as possible contenders in the coming transition to NMDA mediated antidepressant therapy.